Targets › XDH
14 programs from 12 companies in 16 trials: 6 Phase 2, 4 Phase 3, 3 Phase 1, 3 Phase 4; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Nov 2026.
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. (UniProt, P47989)
Open in Phaseline: the race on XDH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bangladesh Medical University | Allopurinol Xanthine dehydrogenase inhibitor | XDH | Phase 4 | Cirrhoses, Liver | Dec 2026 |
| Seoul National University Hospital | Febuxostat Xanthine dehydrogenase inhibitor | XDH | Phase 4 | Gout | Feb 2027 |
| Massachusetts General Hospital | Allopurinol Xanthine dehydrogenase inhibitor | XDH | Phase 4 | Gout | Sep 2028 |
| Arthrosi Therapeutics | XOI High Dose Xanthine oxidase inhibitor | XDH | Phase 3 | Gout | Nov 2026 |
| Innovent Biologics Technology Limited (Shanghai R&D Center) | Tigulixostat (IBI128) Xanthine dehydrogenase inhibitor | XDH | Phase 3 | Gout | Apr 2027 |
| Poznan University of Medical Sciences | Allopurinol Xanthine dehydrogenase inhibitor | XDH | Phase 3 | Cardiovascular Diseases | Jul 2028 |
| dr. M.J.N.L. Benders | Allopurinol Xanthine dehydrogenase inhibitor | XDH | Phase 3 | Congenital Heart Disease in Children | Dec 2028 |
| Arthrosi Therapeutics | XOI Low Dose Xanthine oxidase inhibitor | XDH | Phase 2 | Gout | Nov 2026 |
| Tanta University | Febuxostat Xanthine dehydrogenase inhibitor | XDH | Phase 2 | Non Alcoholic Steatohepatitis; Intracranial Hemorrhage | Dec 2026 |
| Tanta University | Allopurinol Xanthine dehydrogenase inhibitor | XDH | Phase 2 | Depression | May 2027 |
| Maastricht University Medical Center | Febuxostat Xanthine dehydrogenase inhibitor | XDH | Phase 2 | Non-Small Cell Lung Cancer | Jun 2027 |
| Shenyang Sunshine Pharmaceutical | SSS11 (Pegylated Recombinant Candida Utilis Uricase) Urate oxidase - converts uric acid to allantoin | XDH | Phase 1 | Gout | Dec 2026 |
| Shanghai Institute Of Biological Products | SIBP-R002 (Peguricase for injection) Non-selective xanthine oxidase inhibitor | XDH | Phase 1 | Gout | Dec 2026 |
| Fujita Health University | Febuxostat Xanthine dehydrogenase inhibitor | XDH | Phase 1 | Parkinson's Disease (PD) | – |
Gout (8) Non Alcoholic Steatohepatitis (1) Intracranial Hemorrhage (1) Non-Small Cell Lung Cancer (1) Parkinson's Disease (PD) (1) Depression (1) Cirrhoses, Liver (1) Congenital Heart Disease in Children (1) Cardiovascular Diseases (1)
small molecule (11), mixed (2), protein or peptide (1)
Tanta University (2) Arthrosi Therapeutics (2) Maastricht University Medical Center (1) Fujita Health University (1) Seoul National University Hospital (1) Bangladesh Medical University (1) dr. M.J.N.L. Benders (1) Poznan University of Medical Sciences (1) Massachusetts General Hospital (1) Shenyang Sunshine Pharmaceutical (1) Shanghai Institute Of Biological Products (1) Innovent Biologics Technology Limited (Shanghai R&D Center) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.